Paratus Clinical

What Paratus Clinical does

Paratus Clinical is a privately held Australian site management organisation (SMO) that operates purpose-built clinical research sites to conduct Phase I-IV trials on behalf of pharmaceutical, biotechnology, and medical device sponsors. Founded in 2015 by Matt Clacy and headquartered in Chatswood, New South Wales, the company runs five wholly-owned clinics along Australia's east coast spanning Queensland (Brisbane/Herston), New South Wales (Western Sydney/Blacktown, Central Coast/Kanwal), Australian Capital Territory (Canberra/Bruce and Woden), and Victoria (Melbourne/Northcote), with trans-Tasman reach into New Zealand via a February 2026 partnership with Waitemata Clinical Research in Auckland. Its commercial focus is enterprise pharma/biotech sponsors and CROs seeking efficient study start-up, regulatory speed, and high-performing participant recruitment, with documented therapeutic coverage spanning vaccines, dermatology, metabolic disease, cardiovascular, respiratory, mental health, and an emerging psychiatry/psychedelic-assisted therapy vertical through the 2025 Melbourne Northcote site.

Core technology and operating capabilities sit on a centralised, hub-and-spoke architecture. Centralised functions include a dedicated in-house Participant Recruitment team (digital advertising, community engagement, and GP/specialist referral pathway management) and a Study Start-up team handling HREC submissions through Bellberry Ltd, with an average 38 working days from submission to approval. Site-level operations run on a third-party RealTime Clinical Trial Management System (CTMS) with CFR 21 Part 11 compliant electronic source documentation and remote monitoring access; each site holds PC1 certification from the Office of the Gene Technology Regulator, enabling GMO-containing vaccine and gene therapy trials, and a TransCelerate Biopharma-approved ICH GCP training programme governs staff certification. Multiple sites are co-located with high-throughput general practices (Eastbrooke Medical Centre Blacktown, Ochre Health Bruce, Next Practice Brisbane) and a dermatology practice (Woden Dermatology), creating structural referral pipelines.

The business model is professional-services clinical trial conduct billed on a per-study basis to sponsors, with reimbursement amounts varying materially by study type and duration (e.g., $190 per visit for relapse-prevention trials through to $4,420 for an 84-week weight loss trial). Distribution combines an enterprise field-sales motion targeting sponsor decision-makers (led by Founder/CCO Matt Clacy) with referral-driven recruitment from co-located medical practices and adjacent clinical partners. Capital is limited: the company raised approximately A$1.08M in October 2017 from Carthona Capital and Cthulhu Ventures following an undisclosed 2015 founder funding round, indicating growth has been funded primarily through operating cash flow and reinvestment. Growth has been driven by site openings (2016 Central Coast, 2019 Canberra and Western Sydney, 2025 Melbourne Northcote), strategic partnerships (Torquay 2025, Cognivus September 2025, Waitemata February 2026), and the July 2025 appointment of CEO Megan Morrison to professionalise operations.

Name

Paratus Clinical

Legal name

Paratus Clinical Pty Ltd

Website

https://paratusclinical.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Paratus Clinical is an Australian site management organisation operating five wholly-owned clinical research sites along the east coast plus a New Zealand partnership. It conducts Phase I-IV trials for pharmaceutical, biotech, and medical device sponsors across vaccines, dermatology, metabolic, and mental health indications.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)

SIC

Services-Misc Health & Allied Services, Nec (8090), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts) (HLAGACAC), Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG), Clinical Trial Financial Management & Payments (Site Budgeting) (HLAGACAM)

Keywords

• Clinical trial services
• Participant recruitment
• Site management organisation
• Vaccine clinical trials
• Phase I-IV trials

Headquarters

HQ city

North Sydney

HQ country

Australia

HQ region

Oceania

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Clinical Trial Conduct Services: Paratus Clinical conducts Phase I-IV clinical trials across multiple therapeutic areas for pharmaceutical companies, biotech firms, CROs, and medical device companies. Revenue is generated through contracted research services, typically per-study agreements with sponsors.
2. Participant Recruitment Services: Dedicated recruitment team provides participant recruitment services to support trial recruitment targets, including database management, community outreach, and digital advertising campaigns.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Paratus Clinical operates a network of wholly-owned clinical research sites across Australia's East Coast (Brisbane, Western Sydney, Central Coast, Melbourne, Canberra) plus strategic partnerships in New Zealand and Victoria. The company conducts Phase I-IV clinical trials for pharmaceutical, biotech, CRO, and medical device sponsors across therapeutic areas including vaccines, dermatology, mental health, metabolic disorders, and cardiovascular disease. Services encompass study start-up via Bellberry ethics committee, centralized participant recruitment, PC1 certified facilities for GMO studies, and a RealTime Clinical Trial Management System with CFR 21 Part 11 compliant electronic source documentation.

Product overview

Paratus Clinical operates as a clinical research organization offering an integrated network of clinical trial services across Australia's East Coast. The portfolio consists of a network of five wholly-owned purpose-built clinical trial sites (Brisbane, Western Sydney, Central Coast, Melbourne Northcote, and Canberra) supported by centralized functions including participant recruitment services, study start-up processes, and a proprietary Clinical Trial Management System (RealTime CTMS). The company delivers Phase I-IV clinical trials across multiple therapeutic areas including vaccines, metabolic/weight management, cardiovascular, dermatology, mental health, respiratory, and diabetes. Recent expansion includes strategic partnerships with sites in Victoria and New Zealand, and a new Melbourne Northcote facility specializing in psychiatric research including psychedelic-assisted therapy trials.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Site Network Network of five wholly-owned purpose-built clinical research sites across Australia's East Coast (Brisbane, Western Sydney, Central Coast, Melbourne Northcote, Canberra) plus strategic partnership sites in Victoria and New Zealand, delivering Phase I-IV clinical trials to pharmaceutical, biotech, CRO, and medical device sponsors.
• Centralized Participant Recruitment Services Dedicated in-house recruitment team providing pre-screening, participant identification, and database management across all clinic sites. Includes digital advertising campaigns, GP and specialist referral network coordination, and community outreach to support sponsor recruitment targets.
• Study Start-up Services Centralized study start-up process with specialized staff for HREC submissions and critical document handling, partnering with Bellberry Ltd for ethics approvals with average 38 working days from submission to approval.
• PC1 Certified Facility Services Office of the Gene Technology Regulator (OTGR) accredited PC1 Facilities at each site enabling conduct of clinical trials involving genetically modified organisms (GMOs).
• Melbourne Northcote Psychiatry Trials Facility Purpose-built Melbourne Northcote facility opened in 2025 specializing in primary care and psychiatry trials, with therapy suites enabling psychedelic-assisted therapy research and novel psychiatric protocols.
• RealTime Clinical Trial Management System Implemented Clinical Trial Management System called RealTime for tracking and managing all trial activity, including database search tools, eligibility questions, calendar notifications, and generation of text/email communications to participants. Includes CFR 21 Part 11 compliant electronic source documentation with remote monitoring access.

Quantifiable outcome

• 38 working days average HREC approval time through Bellberry Ltd
• +7 more outcomes

Named customers8 records

Segments7 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Waitemata Clinical ResearchcoreStrategic or Co-development Partner · 17 February 2026Strategic partnership with Waitemata Clinical Research in Auckland, New Zealand. Combines Paratus' centralised functions with Waitemata's established investigator-led Auckland site, providing a stronger trans-Tasman clinical trial delivery option. Waitemata has 4,550 active participants.
• Cognivus Research GroupcoreStrategic or Co-development Partner · 8 September 2025Partnership with Cognivus Research Group expanding specialist research beyond hospital settings.
• Clinical Trials InstitutecoreStrategic or Co-development Partner · 20 March 2025Partnership with Clinical Trials Institute at Torquay, Victoria operated out of Medical Hub. Provides access to referral pathways spanning 48+ general practitioners, 10+ specialist investigators, a dedicated team of 25 research nurses, and a participant database of more than 350,000 people.
• Bellberry LtdcoreStrategic or Co-development PartnerPrivate non-profit ethics committee partnership enabling efficient HREC processing with an average of 38 working days from submission to approval, well ahead of most public health institutions.
• Society for Clinical Research Sites (SCRS)minorOthersProud member of Society for Clinical Research Sites. Actively participates in discussions and decisions impacting the industry, and partakes in industry training and events.
• Ochre Health BrucecoreChannel Partner/ Reseller/ DistributorCo-located GP practice with 23 practicing GPs at University of Canberra campus. Strong GP referral pathways fueling the decision to establish independent clinic for greater research volumes.
• Eastbrooke Medical CentrecoreChannel Partner/ Reseller/ DistributorCo-located medical centre in Blacktown with 14 practicing GPs providing strong referral pathways for Western Sydney clinic.
• Next Practice Medical ClinicminorChannel Partner/ Reseller/ DistributorAffiliated medical clinic opposite Royal Brisbane Hospital with 9 practicing GPs. Referral pathways support Brisbane site recruitment.
• Woden DermatologycoreChannel Partner/ Reseller/ DistributorCo-located dermatology practice near Canberra Hospital. Provides dedicated facility for dermatology and haematology clinical research with established patient base.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Market position

Competitive moat4 records

Key highlights7 records

Customer concentration

• Xx.com/paratusclinical
• LinkedInlinkedin.com/company/3107402

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Paratus Clinical